For Iraq Veterans, Headaches Continue After Traumatic Brain Injury
Posted on: Tuesday, 24 February 2009, 09:16 CST
The study, conducted at
Nearly 98 percent of the soldiers reported having headaches during the last three months of their deployment. The headaches started within one week of the traumatic brain injury for 37 percent of the soldiers, and within one to four weeks for 20 percent. Among the soldiers whose headaches started within a week of the injury, 60 percent had migraine-like headaches and 40 percent had headaches that interfered with their ability to do their daily activities. Thirty percent had headaches for 15 or more days each month.
"Mild traumatic brain injury is occurring in 15 to 25 percent of soldiers deployed to
The study was supported by
The American Academy of Neurology, an association of more than 21,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as multiple sclerosis, restless legs syndrome, Alzheimer's disease, narcolepsy, and stroke.
For more information about the American Academy of Neurology, visit www.aan.com.
The AAN 61st Annual Meeting, the world's largest gathering of neurology professionals, takes place
To access 2009 AAN Annual Meeting abstracts available
Late-breaking abstracts will be featured in press release at the 2009 AAN Annual Meeting in
SOURCE American Academy of Neurology
Source: PR Newswire
Related Articles
- Kessler Foundation Research Center Presented Two Studies on Post-stroke Spatial Neglect at American Academy of Neurology
- New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting
- Lippincott Williams & Wilkins and the American Academy of Neurology Renew Publishing Partnership
- Bayhill Therapeutics Presents Data From a Phase II Trial of BHT-3009 in Multiple Sclerosis at American Academy of Neurology 60th Annual Meeting
- Acorda Therapeutics Presents Data From Its Phase 3 Study of Fampridine-SR in Multiple Sclerosis at the American Academy of Neurology Meeting
- Accera, Inc. To Present Results of Phase II Study in Alzheimer's Disease at American Academy of Neurology Meeting
- American Academy of Dermatology: Study Finds Women Twice As Likely As Men to Seek Treatment for Hyperhidrosis
- SCHWARZ PHARMA Presents Clinical Data on Rotigotine Transdermal Patch at the Annual Meeting of the American Academy of Neurology
- NMT Medical to Present MIST Trial Results on April 5th at the American Academy of Neurology's Annual Meeting
- AVANIR's Pivotal Neurodex Clinical Trial Data Presented at American Academy of Neurology Meeting; Data on the Treatment of PBA in MS Patients Selected As a ``Highlight of the Meeting''
User Comments (0)

RSS Feeds